Business

CNL Launches Program to Accelerate Target Radiopharmaceutical Development in Canada, Canadian Business Journal

GLOBE NEWSWIRE, Ontario, November 25, 2021 — Canadian Nuclear Laboratories (CNL), Canada’s leading nuclear science and technology organization, is its Canadian Nuclear Research Initiative (CNRI). The new program provides access to world-class laboratories and research functions on the Chalk River Laboratories Campus through collaborative research projects related to health sciences, radiobiology, and medical isotope development to target radioactivity in Canada. Designed to accelerate drug development.

The CNRI program, launched in 2019, was initially established by CNL to promote the deployment of small modular reactors (SMRs) and advanced reactor design. With continued interest in this program, CNL has expanded CNRI to another important area of ​​expertise, health sciences, with participants accessing company-specific facilities and personnel to collaborate with CNL on research. It is now possible.

“With over a billion medical treatments using isotopes manufactured at the Chalk River Institute, CNL’s work has impacted the lives of people around the world,” said CNL’s president and CEO. Joe McBrearty commented. “Today, we continue to pursue this mission as a full-service nuclear laboratory with the ability to carry out cutting-edge drug development, along with extensive radiochemical analysis. Through our extended CNRI program, I continue to pursue this mission. We want to make better use of our resources, focus on cancer treatment, and help people suffering from a variety of medical problems. “

For the initial intake of the program, research proposals should be consistent with topics including targeted delivery systems, toxicology, and preclinical evaluation. After completing the technical review of each proposal, CNL will work with the proposer to develop a plan to establish the scope, budget, and deliverables of the project. CNL completes the final evaluation of the proposed project plan before making the final selection and approval of successful applicants. The deadline for submission is January 15, 2022, and the project will be selected in the spring of 2022.

CNL has been a global leader in medical isotopes and related research for over 70 years, pioneering the use of Cobalt-60 radiation therapy for the treatment of cancer, and a leading producer of molybdenum-99 supplies worldwide. Has played a role as. Used in diagnostic procedures. CNL currently has a variety of functions in the areas of health and dosimetry, including preclinical animal research, isotope production and treatment, in vitro drug evaluation, targeted radionuclide therapy, ISO-certified analytical chemistry services, and waste management solutions. I’m keeping it.

“The CNRI program has been very successful in developing SMR and other advanced reactor technologies and encouraged the application of this collaborative model to other areas of research,” said CNL’s Vice President of Science and Technology. Dr. Jeff Griffin commented. .. “We believe that organizations seeking research on radiopharmaceutical discovery, toxicology, and preclinical efficacy have unmet needs. This program is a means to drive innovative solutions in these areas. Useful as. “

Apart from CNRI, CNL is working to establish itself as an international hub in the research, development and supply of next-generation medical isotopes and radiopharmaceuticals, including actinium 225. Edge cancer treatment. As part of these efforts, CNL recently signed a memorandum of understanding with ITM Isotope Technologies Munich SE to investigate the development and industrial scale production of Actinium 225.

For more information on CNL and its commitments in health science, please visit www.cnl.ca/health. For more information on CNRI Health Stream, including submission guidelines and details, please visit www.cnl.ca/cnri-health.

About CNL
Canadian Nuclear Laboratories are world leaders in nuclear science and technology, providing unique features and solutions to a wide range of industries. Actively involved in industry-led R & D in nuclear, transportation, clean technology, energy, defense, security and life sciences, providing solutions to keep these sectors internationally competitive. ..

With continued investment in new facilities and focused missions, the Canadian Atomic Energy Institute is in a good position for the future. New performance standards, strengthened by a strong safety culture, underscore all activities.

For more information on the full range of Canadian Atomic Energy Institute services, please visit www.cnl.ca or contact communications @ cnl.ca.

CNL contact:
Patrick Quinn
Corporate Communication Director
Phone number: 1-866-886-2325
Email: communications@cnl.ca

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/869ef61d-4a19-4c86-93d9-47ca287adbd3.


CBJ News Maker

CNL Launches Program to Accelerate Target Radiopharmaceutical Development in Canada, Canadian Business Journal

Source link CNL Launches Program to Accelerate Target Radiopharmaceutical Development in Canada, Canadian Business Journal

Related Articles

Back to top button